by Peter Ciszewski | Sep 22, 2021
Kah Poh (Melissa) Loh, BMedSci, MBBCh, BAO, Geriatric Hematologist and Oncologist at Strong Memorial Hospital, discusses her recent study on treatment decision-making in older adults with acute myeloid leukemia (AML). AML is a blood cancer that most often...
by Peter Ciszewski | Sep 21, 2021
Saad Usmani, MD, FACP, Division Chief of Plasma Cell Disorders and Director of Clinical Research in Hematological Malignancies at Levine Cancer Institute, discusses potential future uses of cilta-cel, an investigational treatment for relapsed/refractory...
by Peter Ciszewski | Sep 17, 2021
Tracy Dixon-Salazar, PhD, Executive Director of the Lennox-Gastaut Syndrome (LGS) Foundation, gives an overview of the disease and what the foundation is doing to help this patient community. As Dr. Dixon-Salazar explains, LGS is a rare neurological condition...
by Peter Ciszewski | Sep 16, 2021
Nina Shah, MD, Hematologist from the University of California, San Francisco, discusses the potential use of natural killer (NK) cells as a treatment for multiple myeloma. Multiple myeloma is a rare blood cancer associated with uncontrolled growth of myeloma cells...
by Peter Ciszewski | Sep 15, 2021
The U.S. Food and Drug Administration (FDA) has granted accelerated approval of zanubrutinib (Brukinsa) to treat adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. MZL is a group of...
